Immunotherapy Boosts Chemotherapy Cutting Recurrence Risk by 50% in St-3 dMMR Colon Cancer

Adding atezolizumab to adjuvant mFOLFOX6 significantly improved outcomes in resected stage III dMMR colon cancer, reducing recurrence or death risk by 50% versus chemotherapy alone. In the phase 3 ATOMIC trial, 3-year disease-free survival reached 86.3% with the combination, compared with 76.2% for mFOLFOX6 alone, supporting a new biomarker-driven standard of care.

For years, adjuvant treatment for stage III colon cancer has followed a familiar script: surgery first, then oxaliplatin-based chemotherapy to lower the risk of recurrence. But that approach has always been less satisfying in one biologically distinct subgroup, tumors with deficient DNA mismatch repair, or dMMR. These cancers, found in roughly 15% of patients with colon cancer, tend to respond less well to conventional chemotherapy alone.

Now a large phase 3 trial suggests that this therapeutic gap can be narrowed, and perhaps decisively. In patients with resected stage III dMMR colon cancer, adding the PD-L1 inhibitor atezolizumab to adjuvant mFOLFOX6 significantly improved disease-free survival compared with chemotherapy alone, cutting the risk of recurrence or death by 50%.

Early Findings Presented at the ASCO Annual Meeting

The study, published in the New England Journal of Medicine, enrolled 712 patients with surgically removed, node-positive, stage III dMMR colon cancer. Participants were randomly assigned in a 1:1 ratio to receive either atezolizumab plus modified FOLFOX6 for six months, followed by atezolizumab alone to complete 12 months of therapy, or mFOLFOX6 alone for six months.

"The findings from our study represent a major advance in the adjuvant treatment of dMMR stage 3 colon cancer and will now change clinical practice," says Dr. Frank Sinicrope, a Mayo Clinic oncologist who led the study. “It's very rewarding to be able to offer our patients a new treatment regimen that can reduce the risk of recurrence and improve their chances of survival.”

Atezolizumab Delivers a Clear DFS Benefit

The results were clinically meaningful and statistically robust. At a median follow-up of 40.9 months, 3-year disease-free survival reached 86.3% in the atezolizumab-plus-mFOLFOX6 group, compared with 76.2% in the chemotherapy-alone arm. The hazard ratio for recurrence or death was 0.50, with a 95% confidence interval of 0.35 to 0.73, and a P value of less than 0.001.

This was not a small or unusually selected population. The median age was 64 years, 55.1% of patients were women, and 53.9% had high-risk disease defined as T4, N2, or both. The trial also included patients with Lynch syndrome, the most common inherited form of colon cancer, a relevant detail because these tumors are frequently dMMR and often present at younger ages.

Why dMMR Tumors Are Primed for Immunotherapy

dMMR tumors accumulate replication errors and typically harbor a more inflamed microenvironment, including immune cell populations that may be particularly susceptible to checkpoint blockade. That immunologic background has already made dMMR colorectal cancer a compelling target in the metastatic setting. What ATOMIC shows is that the same biology can now be exploited earlier, when the disease burden is lower and the therapeutic goal is cure.

The safety tradeoff, however, deserves attention. Grade 3 or 4 adverse events occurred in 84.1% of patients receiving atezolizumab plus mFOLFOX6, versus 71.9% in the mFOLFOX6-alone group. That increase is not trivial, especially in the adjuvant setting, where tolerability matters as much as efficacy. Still, the magnitude of benefit is likely to outweigh those concerns for many clinicians, particularly given the historically limited sensitivity of dMMR tumors to chemotherapy.

Implications Extend Beyond the Trial Findings

According to Mayo Clinic, NCCN guidelines have been updated to include this regimen as a recommended treatment, not only for stage III dMMR colon cancer but also for selected patients with high-risk stage II disease in whom the tumor invades or adheres to adjacent structures without nodal involvement.

"We're changing the paradigm in colon cancer treatment. By using immunotherapy at earlier stages of disease, we are achieving meaningful benefits for our patients," says Dr. Sinicrope.

In colon cancer, immunotherapy has long been seen as transformative, but largely for advanced disease. This study suggests the field is entering a new phase, one in which biomarker-driven immunotherapy is no longer reserved for recurrence, but used to prevent it.